National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 51205 [2016-18391]
Download as PDF
<![CDATA[
51205
Federal Register / Vol. 81, No. 149 / Wednesday, August 3, 2016 / Notices
imposed by this regulation. The written
agreement generally also includes
contractual agreements that are a usual
and customary business practice. The
recordkeeping requirements of
§ 801.150(a)(2) consist of making copies
and maintaining the records required
under the third-party disclosure section
of this collection.
In the Federal Register of April 20,
2016 (81 FR 23309), FDA published a
60-day notice requesting public
comment on the proposed collection of
information. No comments were
received.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL RECORDKEEPING BURDEN
Number of
recordkeepers
21 CFR section
Record retention, 801.150(a)(2) ..........................................
Number of
records per
recordkeeper
90
Total annual
records
20
Average
burden per
recordkeeping
(hours)
1,800
Total hours
.5
900
TABLE 2—ESTIMATED ANNUAL THIRD-PARTY DISCLOSURE BURDEN
Number of
respondents
Activity/21 CFR section
Agreement and labeling requirements, 801.150(e) .............
Dated: July 28, 2016.
Leslie Kux,
Associate Commissioner for Policy.
Office of the Secretary
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Delegation of Authorities
Notice is hereby given that I have
delegated to the Commissioner of Food
and Drugs (the Commissioner) those
authorities vested in the Secretary of the
Department of Health and Human
Services under sections 1002; 1003;
1004; 1005(f); and 1006(b) and (d) of the
Food and Drug Administration
Amendments Act of 2007 (Pub. L. 110–
85), which relate to the functions of the
Food and Drug Administration.
This authority may be re-delegated.
This delegation will be exercised in
accordance with the Department of
Health and Human Services’ applicable
policies, procedures, guidelines, and
regulations.
I ratify and affirm any actions taken
by the Commissioner or the
Commissioner’s subordinates that
involved the exercise of the authority
delegated herein prior to the effective
date of this delegation. This delegation
was effective on November 17, 2015.
VerDate Sep<11>2014
18:21 Aug 02, 2016
Jkt 238001
1,800
Total hours
4
7,200
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: July 28, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE P
20
Average
burden per
disclosure
(hours)
National Institutes of Health
BILLING CODE 4164–01–P
[FR Doc. 2016–18417 Filed 8–2–16; 8:45 am]
90
Total annual
disclosures
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2016–18299 Filed 8–2–16; 8:45 am]
Dated: July 27, 2016.
Sylvia M. Burwell,
Secretary.
Number of
disclosures
per
respondent
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID SBIR Phase II
Clinical Trial Implementation (U44).
Date: August 30, 2016.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 3F100,
5601 Fishers Lane, Rockville, MD 20892,
(Telephone Conference Call).
Contact Person: Lynn Rust, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room 3G42A, National Institutes of Health/
NIAID, 5601 Fishers Lane, MSC 9823,
Bethesda, MD 20892–9823, (240) 669–5069,
lrust@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
[FR Doc. 2016–18391 Filed 8–2–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
[Docket No. SAMHSA–2016–0002]
Request for Comment on Report
Entitled: Advancing the Care of
Pregnant and Parenting Women With
Opioid Use Disorder and Their Infants:
A Foundation for Clinical Guidance
Substance Abuse and Mental
Health Services Administration
(SAMHSA), Department of Health and
Human Services (HHS).
ACTION: Request for comment.
AGENCY:
SAMHSA, Center for
Substance Abuse Treatment (CSAT), in
HHS announces the opening of a docket
to obtain public comment on a report
entitled: Advancing the Care of Pregnant
and Parenting Women with Opioid Use
Disorder and their Infants: A
Foundation for Clinical Guidance.
This report describes the formal
process agreed on and followed under
the guidance of the federal steering
committee (FSC). It explains the RAND
Corporation (RAND)/University of
California Los Angeles (UCLA)
SUMMARY:
E:\FR\FM\03AUN1.SGM
03AUN1
]]>Agencies
[Federal Register Volume 81, Number 149 (Wednesday, August 3, 2016)]
[Notices]
[Page 51205]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-18391]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; NIAID SBIR Phase II Clinical Trial
Implementation (U44).
Date: August 30, 2016.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 3F100, 5601 Fishers Lane,
Rockville, MD 20892, (Telephone Conference Call).
Contact Person: Lynn Rust, Ph.D., Scientific Review Officer,
Scientific Review Program, Division of Extramural Activities, Room
3G42A, National Institutes of Health/NIAID, 5601 Fishers Lane, MSC
9823, Bethesda, MD 20892-9823, (240) 669-5069, lrust@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: July 28, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-18391 Filed 8-2-16; 8:45 am]
BILLING CODE 4140-01-P
